

5122-40-11

**Toxicology.**

Each ~~methadone~~-opioid treatment program shall have written procedures for toxicology screening that include, at a minimum:

- (A) Requirement that an initial toxicology screening be performed for each prospective ~~methadone~~ patient as part of the documented physical evaluation completed by a physician prior to admission. The results of all tests must be received within fourteen days following admission.
- (B) Requirement that a toxicology screening be performed monthly for each ~~methadone~~ patient.
  - (1) This requirement may be reduced to two toxicology screenings per quarter if the patient has had more than twenty-four consecutive months of negative screens.
  - (2) The failure of a toxicology screening due to illicit drug use shall result in a return to monthly screening.
- (C) Requirement that programs shall have a standing physician's order for patient toxicology screening.
- (D) Requirement that any urine screen sent in for confirmation be performed by a laboratory that is in compliance with all "Clinical Laboratory Improvement Amendments" per 42 C.F.R. 493.
- (E) Requirement that toxicology screening be conducted in a manner to minimize falsification and that sample collection procedures include the following:
  - (1) Each specimen collection will be monitored.
  - (2) Each sample shall be labeled to reflect the identification of the person from whom it was obtained and reflect the date the sample was obtained.
- (F) Requirements that each toxicology screening include, at a minimum analysis for the following:
  - (1) Opiates, including prescription opioid analgesics as defined in section 3719.01 of the Revised Code, heroin, and fentanyl;
  - (2) Methadone;
  - (3) Amphetamines;
  - (4) Cocaine;

- (5) Barbiturates;
  - (6) Marijuana;
  - (7) Benzodiazepines, as defined in section 3719.01 of the Revised Code; and,
  - (8) Buprenorphine.
- (G) Results of toxicology screening shall be reviewed by the program staff with the patient with documentation of such and a copy of the results placed in the patient's file, in accordance with the requirements of rule 5122-27-04 of the Administrative Code.
- (H) Provisions for ensuring that presumptive laboratory results are distinguished from confirmatory laboratory results.
- (I) The program shall have a policy for the discontinuation of ~~methadone~~-medication maintenance for individuals who test positive for illicit drugs, which shall include provisions for continuing to provide counseling and other rehabilitation services, or referral to another provider.

Effective: 1/1/2019

Five Year Review (FYR) Dates: 6/1/2022

CERTIFIED ELECTRONICALLY

---

Certification

11/05/2018

---

Date

Promulgated Under: 119.03  
Statutory Authority: 5119.391  
Rule Amplifies: 5119.391  
Prior Effective Dates: 07/01/2001, 10/01/2003, 06/01/2017